tetano
Editor, Senior Moderator
Hum Vaccin Immunother. 2019 Sep 30. doi: 10.1080/21645515.2019.1672492. [Epub ahead of print] [h=1]Adjuvanted-influenza vaccination in patients infected with HIV: A systematic review and meta-analysis of immunogenicity and safety.[/h]
Chen YC[SUP]1[/SUP], Zhou JH[SUP]1[/SUP], Tian JM[SUP]1[/SUP], Li BH[SUP]1[/SUP], Liu LH[SUP]1[/SUP], Wei K[SUP]1[/SUP].
[h=3]Author information[/h] 1 Medical school, Hunan University of Chinese Medicine , Changsha Hunan 410208 China.
[h=3]Abstract[/h] Adjuvanted-influenza vaccination is an efficient method for enhancing the immunogenicity of influenza split-virus vaccines for preventing influenza. However, the medical community's understanding of its performance in patients infected with HIV remains limited. To identify the advantages, we conducted a systematic review and meta-analysis with randomized controlled trials (RCTs) and cohort and case-control studies that have the immunogenicity and safety of influenza vaccines in patients infected with HIV as outcomes. We searched six different databases, and 1698 patients infected with HIV in 11 studies were included. Statistical analysis was performed to calculate the pooled standardized mean differences (SMD) or relative risk (RR) and 95% confidence interval (CI). Regarding immunogenicity, the pooled SMD of GMT (Geometric mean titer) for A/H1N1 was 0.61 (95%CI (0.40,0.82)), the pooled RR of seroconversion was 1.34 (95%CI (0.91,1.98)) for the H1N1 vaccine, 1.27(95%CI (0.64,2.52)) for the H3N2 vaccine, 1.19(95%CI (0.97,1.46)) for the B-type influenza vaccine. The pooled RR of seroprotection was 1.61 (95%CI (1.00,2.58)) for the H1N1 vaccine, 1.06 (95%CI(0.83,1.35)) for the H3N2 vaccine, and 1.13(95%CI(0.91,1.41)) for the B-type vaccine. Adjuvanted-influenza vaccination showed good general tolerability in patients infected with HIV, with the only significant increase being the rate of local pain at the injection site (RR = 2.03, 95%CI (1.06,3.86)). In conclusion, all studies evaluating injected adjuvanted influenza vaccination among patients infected with HIV showed acceptable levels of safety and immunogenicity.
[h=4]KEYWORDS:[/h] Adjuvant; HIV; Immunogenicity; Influenza vaccine; Meta-Analysis
PMID: 31567058 DOI: 10.1080/21645515.2019.1672492
Chen YC[SUP]1[/SUP], Zhou JH[SUP]1[/SUP], Tian JM[SUP]1[/SUP], Li BH[SUP]1[/SUP], Liu LH[SUP]1[/SUP], Wei K[SUP]1[/SUP].
[h=3]Author information[/h] 1 Medical school, Hunan University of Chinese Medicine , Changsha Hunan 410208 China.
[h=3]Abstract[/h] Adjuvanted-influenza vaccination is an efficient method for enhancing the immunogenicity of influenza split-virus vaccines for preventing influenza. However, the medical community's understanding of its performance in patients infected with HIV remains limited. To identify the advantages, we conducted a systematic review and meta-analysis with randomized controlled trials (RCTs) and cohort and case-control studies that have the immunogenicity and safety of influenza vaccines in patients infected with HIV as outcomes. We searched six different databases, and 1698 patients infected with HIV in 11 studies were included. Statistical analysis was performed to calculate the pooled standardized mean differences (SMD) or relative risk (RR) and 95% confidence interval (CI). Regarding immunogenicity, the pooled SMD of GMT (Geometric mean titer) for A/H1N1 was 0.61 (95%CI (0.40,0.82)), the pooled RR of seroconversion was 1.34 (95%CI (0.91,1.98)) for the H1N1 vaccine, 1.27(95%CI (0.64,2.52)) for the H3N2 vaccine, 1.19(95%CI (0.97,1.46)) for the B-type influenza vaccine. The pooled RR of seroprotection was 1.61 (95%CI (1.00,2.58)) for the H1N1 vaccine, 1.06 (95%CI(0.83,1.35)) for the H3N2 vaccine, and 1.13(95%CI(0.91,1.41)) for the B-type vaccine. Adjuvanted-influenza vaccination showed good general tolerability in patients infected with HIV, with the only significant increase being the rate of local pain at the injection site (RR = 2.03, 95%CI (1.06,3.86)). In conclusion, all studies evaluating injected adjuvanted influenza vaccination among patients infected with HIV showed acceptable levels of safety and immunogenicity.
[h=4]KEYWORDS:[/h] Adjuvant; HIV; Immunogenicity; Influenza vaccine; Meta-Analysis
PMID: 31567058 DOI: 10.1080/21645515.2019.1672492